Background: Our report summarizes and compares the characteristics of six prospective, multicenter, randomized clinical trials of carotid endarterectomy underway in North America and Europe.
S ix prospective, multicenter, randomized trials designed to determine the safety and effectiveness of carotid endarterectomy are now being conducted in North America and Europe. The asymptomatic trials include Asymptomatic Carotid Atherosclerosis Study (ACAS), 1 -3 Asymptomatic Carotid Stenosis Veterans Administration Study (VA #167), 4 -6 and Carotid Artery Stenosis With Asymptomatic Narrowing: Operation Versus Aspirin (CASANOVA) 7 -9 ; the symptomatic trials, European Carotid Surgery Trial (ECST), 10 -11 North American Symptomatic Carotid Endarterectomy Trial (NASCET), 12 -16 and Symptomatic Carotid Stenosis Veterans Administration Trial (VA #309). 17 - 18 A seventh trial, the Mayo Asymptomatic Carotid Endarterectomy Study (MACE), is not included in this summary because the majority of patients were recruited from only one center and the trial has been terminated. 1920 Although the trials resemble one another, they vary in essential features, which may make comparisons of results difficult. Consequently, it is important to contrast the features now so that preparations for future comparisons can be considered. Two of the asymptomatic trials (CASANOVA and VA #167) and two of the symptomatic trials (ECST and NASCET) have already published partial results. 16 The symptomatic studies enroll patients who have had transient ischemic attacks (TIAs) or a minor cerebral infarction in the distribution of the randomized carotid artery. Of the three asymptomatic trials, ACAS and VA #167 access patients with stenosis of a carotid artery supplying an asymptomatic hemisphere; these patients are not necessarily asymptomatic in other vascular distributions. CASANOVA requires that subjects have never had cerebrovascular symptoms in any distribution. The primary outcome events for the asymptomatic trials are similar to the entry criteria for the symptomatic studies. Therefore, taken together, these six trials span the range of candidates for carotid endarterectomy. The inclusion and exclusion criteria, methodology, and statistical considerations of each study are contained in Tables 1-4. Inclusion/Exclusion Criteria The best measure for predicting whether the results of a trial will be applicable to patient care is the eligibility criteria because sampling is seldom done on truly representative patient populations. Furthermore, knowing how the study patients were assembled is important for constructing comparable subgroups across studies.
An inclusion criterion for all six studies is evidence of stenosis. Whether this stenosis is recorded as reduction of lumen diameter or cross-sectional area is important. The minimum degree of stenosis for eligibility in VA #167 and CASANOVA is 50% reduction of lumen diameter; a hemodynamically significant lesion (usually 60% reduction of lumen diameter) is the minimum for ACAS. Patients with highly stenotic disease (>90%) are 3 § In view of variability in the measurement of stenosis by angiography, Doppler, or duplex ultrasonography, the 10% difference in entry criteria for the asymptomatic trials is of little consequence. However, the symptomatic trials have very different entry criteria for stenosis; thus, study comparisons or group analyses should be limited to subgroups with the same degrees of stenosi$. Further, NASCET and ECST measure the stenosis in the origin of the internal carotid artery in slightly different ways, implying that in each stenosis subgroup the ECST patients have, on average, slightly less stenosis than do the NASCET patients. Studies are currently under way to correlate the two methods of measurement.
Other inclusion criteria appear to be comparable among the trials. One exception is that the qualifying event for eligibility in the symptomatic trials can precede randomization by 120 days for VA #309 and NASCET and by 180 days for ECST. Because it has been shown that the period of greatest risk for subsequent infarction after TIA is the first 30 days, delay in randomization beyond this time could miss patients who had died in the meantime.
All six studies exclude patients with a life expectancy of less than the duration of the studies, those with conditions that would interfere with the evaluation of the results, and those with conditions that contraindicate surgery. Also, all studies except NASCET and ECST exclude patients who have aspirin intolerance.
Methodology

Medical Therapy
The requirement for uniformity of medical management for all treatment groups is assured in doubleblinded studies. In these six nonblinded trials of carotid endarterectomy, precautions must be taken to ensure that differences in medical management (such as the follow-up schedule) do not affect the ascertainment of outcome events and that medical management of intercurrent illness is comparable for all treatments.
All the trials are designed to compare medical management plus risk factor reduction with medical management, risk factor reduction, and carotid endarterectomy. NASCET and CASANOVA use 1,300 and 990 mg of aspirin per day, respectively, based on results of previous trials for TIA. However, there are no guidelines for the prophylactic dose of aspirin for patients with asymptomatic carotid stenosis. VA #167 initially used 1,300 mg of aspirin per day but 325 mg was permitted during the last 18 months of the study if patients were intolerant of the higher dose. ACAS and VA #309 use 325 mg per day. ECST permits the use and dosage of aspirin desired by the physician.
Quality Assurance
ACAS, NASCET, VA #167, and VA #309 required retrospective review of surgeons' performance before they were allowed to participate in the trial. ACAS required that a surgeon perform a minimum of 12 endarterectomies annually and that the perioperative and postoperative morbidity and mortality rate be <3%. NASCET required its surgeons to have a 30-day perioperative stroke and death rate of <6% for a minimum of 50 consecutive patients accumulated over 2 years. VA #167 conducted a 2-year retrospective analysis of all consecutive endarterectomy cases at each participating institution before its acceptance into the trial; each institution reported a morbidity and mortality rate of <3%, which became the minimally acceptable level for participation. VA #309 reviewed both the surgeon's and the institution's surgical morbidity and mortality rates for 3 years, 1986-1988; all surgeons and institutions had morbidity and mortality rates of <6%. None of the trials have anesthesia and surgical technique standardized.
Eligible Nonrandomized Patients
ACAS, NASCET, and VA #309 identify all patients who are eligible but not randomized. ACAS and VA #309 collect minimal data on these nonrandomized patients who give consent to be followed. All patients undergoing endarterectomy outside the trial are identified and recorded. VA #309 monitors admission diagnoses of TIA, stroke, and transient monocular blindness.
Statistical Considerations Outcome Events
Ascertainment of outcome events (treatment failures) can be vexing when based on subjective criteria, as is the case for TIA or for stroke recurrence or worsening. Multiple reviewers expressing expert opinions and uniform definitions are often required to standardize the diagnoses and repeatability of the ascertainment. All efforts must be made to ensure that there is minimal ascertainment bias among the treatment groups.
ACAS and VA #167 define their primary outcome events as any TIA or cerebral infarction in the distribution of the randomized artery. In VA #167, death in the 30-day perioperative period is also included in the primary outcome analysis. In the 30-day perioperative period (or 42-day postrandomization period for the medical group) for ACAS, any TIA, stroke (ipsilateral, contralateral, or in the vertebrobasilar territory), or death is counted as a primary outcome event. The primary outcome events for the other asymptomatic trial, CASANOVA, are stroke and death resulting from surgery or stroke.
The main outcome events for ECST include fatal or disabling ipsilateral stroke or surgery-associated death or stroke, i.e., death from any cause within 30 days of surgery or stroke of any pathology or site within those 30 days. In NASCET, the primary outcome event is any fatal or nonfatal stroke ipsilateral to the symptomatic carotid lesion, including stroke or death occurring during the 30-day perioperative period for surgical patients and during a comparable period after randomization for the medical patients. In contrast, the VA symptomatic trial (#309) defines its primary outcome events as cerebral infarctions or crescendo TIAs ipsilateral to the carotid lesion plus death within 30 days of surgery for the surgical group, and it does not include contralateral events. However, in the VA symptomatic (#309) and asymptomatic (#167) trials, all contralateral events are recorded separately, followed, and included in secondary analyses. These differences emphasize the importance of reporting the frequency of each type of event even though the types may be combined in the primary analysis of outcome events. Some of the trials have standardized the diagnosis of TIA, both for eligibility and outcome ascertainment. Even so, there are differences among their definitions. For example, NASCET considers a nondisabling ischemic event as a stroke if appropriate signs or symptoms persist beyond 1 day, whereas ECST requires symptoms to last for more than 7 days. Ideally, subjectivity in diagnosis or definition could be reduced by algorithms common to all studies. Because of the lack of a uniform objective system, the final reports of these trials must contain, or be able to reference, their methods of diagnosis.
Stratification (Blocking) and Randomization
Stratification is used to eliminate extraneous patient characteristics that may affect prognosis. Failure to stratify by important prognostic characteristics may obscure differences between groups by increasing the variability in therapeutic response or by bias if there is an imbalance of prognostic factors. Post hoc stratification or multivariate analysis is often used to accomplish the same end, but some efficiency may be lost compared with prestratification before analysis. Most trials stratify by center to control for differences among clinics and also compare baseline prognostic characteristics to ensure similarity between patients in the treatment groups.
Randomization is performed within strata when there is stratification before analysis. Randomization in multicenter studies may be controlled centrally or locally with appropriate central oversight. Different randomization methods are used in the trials, depending on the circumstances.
Aside from stratification by center, among the six trials there is an obvious difference in stratification by patient characteristics that may affect response. Studies of the natural history of carotid stenosis are insufficient to provide much guidance. Subgroup analysis defined by the proposed strata should yield much new knowledge about the natural history of carotid stenosis.
Sample Size
Sample size is determined by the significance level and the statistical power to detect clinically important treatment differences. In choosing the significance level, investigators are stating the risk of concluding that the treatments are different when, in truth, the differences observed are due to chance alone. Two-sided sample size calculations are appropriate when the investigators have no a priori hypothesis regarding the direction of treatment difference. Sample size calculations based on one-sided hypotheses are appropriate when the investigators postulate that one treatment is equal to or better than the other and that differences in the opposite direction, if observed, would be of little interest. Furthermore, one-sided analyses are acceptable when one treatment group must necessarily undergo a higher initial risk, as recognized in the surgery group.
All six trials use the traditional probability level of 0.05 to delineate statistical significance. Only ACAS and ECST use two-sided sample size calculations. In sacrificing this flexibility, the other four trials have gained power to discover differences in one direction only and thus have reduced their necessary sample size.
Current Status
Two of the asymptomatic studies have closed their case acquisitions (VA #167, ,/V=444, closed in November 1988; and CASANOVA, 7V=410, closed in December 1985); ACAS continues after entering 960 (as of August 1991) of its goal of 1,500 patients. Final analyses for VA #167 are currently being completed because the mean clinical follow-up is now >60 months. 5 CASANOVA found no significant difference in the number of neurological deficits and deaths in two groups of patients, but the design of CASANOVA differs from the other studies in that there is not a group with endarterectomy and a group without. Of the symptomatic trials, NASCET found a clinically and statistically significant benefit of endarterectomy in 659 patients with severe (70-99%) stenosis and has closed recruitment of patients in this category of stenosis. Those who underwent surgery had an absolute reduction of 17% in the risk of ipsilateral stroke at 2 years.
15
- 16 Interim results for 778 patients with severe (70-99%) stenosis in ECST showed that the risks of surgery were significantly outweighed by the later benefits. For example, although 7.5% had a stroke or died within 30 days of surgery, during the following 3 years the surgical patients had a sixfold reduction in the risk of ipsilateral stroke. Recruitment has not officially been closed for these patients; i.e., the "grey area of uncertainty" continues. 11 The ECST found no benefit of endarterectomy among 374 patients with mild (0-29%) stenosis and has closed randomization to such patients. In both NASCET and ECST, the results for patients with moderate (30-69%) stenosis remain unknown, and case acquisition continues in this subgroup.
The third symptomatic trial, VA #309, has stopped recruiting over all strata after randomizing 192 patients. At a mean follow-up of 11.9 months, there is a significant 60% reduction in ipsilateral stroke or crescendo TIA for patients with carotid endarterectomy. In a subgroup analysis of 129 patients with severe stenosis, there is a significant 70% reduction. 
Data Analysis
The analysis of well-designed and well-implemented studies is straightforward and built around the preselected outcome events of TIA, stroke, and death. All trials propose, among other analyses, to compare treatment efficacy with respect to length of time before treatment failure (first outcome event after randomization) by means of survival analysis. A common analysis among studies facilitates easier comparison of the results.
It is mandatory that interim analyses be performed before the specified end of the follow-up period because of ethical concerns about needlessly continuing a study after a significant difference has been convincingly demonstrated or after it is clear that no difference can be demonstrated. The methods and timing of these interim analyses should be specified in advance to protect against increasing the risk of a false-positive finding.
Conclusions
Six multicenter studies designed to ascertain the safety and efficacy of carotid endarterectomy are in progress. Despite differences in their protocols, the results from these trials will be helpful in resolving some of the problems surrounding endarterectomy, provided the similarities and differences in the study designs are considered when interpreting the results.
Physicians must recognize that the place of endarterectomy in the management of carotid stenosis is currently an open question for patients with asymptomatic disease and for symptomatic patients with moderate (30-69%) stenosis. Premature conclusions will increase the challenge to meet recruitment goals and will leave both physicians and patients without answers regarding indications and contraindications for this procedure.
Once the trials have been completed, the maximum information will be obtained by keeping in mind differences and similarities in the protocols. This process could be helped considerably by collaboration among the trials to define comparable subgroups in which unified analyses and statistical overviews might be made. 21 - 22 Additional work to unify entry and outcome event criteria would be helpful.
